Abstract 18861: Effects of Class III Antiarrhythmics on ICD Therapies and Clinical Outcomes: A Meta-analysis of Randomized Controlled Trials

• Published in: Circulation (New York, N.Y.) N.Y.), 2015-11, Vol.132 (Suppl_3 Suppl 3), p.A18861-A18861
• Main Authors: Kancharla, Krishna, Oktay, Ahmet A, Kumar, Shashi, Kaddaha, Firas, Pamidimukala, Chaithanya, El Hayek, Georges, Benjo, Cezar, Molina, Marcos, Kanaan, Salim, Herzog, Eyal, Aziz, Emad, Benjo, Alexandre M
• Format: Article
• Language: English
• ISSN: 0009-7322; 1524-4539
• DOI: 10.1161/circ.132.suppl_3.18861

IntroductionImplantable cardioverter defibrillators (ICD) prolong survival in patients with heart failure, reduced left ventricular ejection fraction (LVEF 0.1, otherwise random effect analysis was performed.ResultsAfter reviewing 2931 articles, seven trials that studied Amiodarone, Sotalol, Azimilide or Celivarone were included. A total of 2117 patients (87% males, mean age 63.8 years, mean LVEF 32.8%) were analyzed. 50.6% of the patients had at least one appropriate ICD therapy delivered and 4.5% died during the follow up. Antiarrhythmic drug usage significantly reduced the number of patients receiving ICD therapy by 55% (OR=0.45, 95% confidence interval [CI] 0.26-0.77, P=.004). There was no significant difference in mortality between treatment and placebo arms. Only 2 of the 7 trials reported number of hospitalizations and the sample size was insufficient for analysis.ConclusionsClass III antiarrhythmics significantly reduced ICD therapy for VA with no significant change in mortality.